If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a clinical trial page for referral information. For more information on Hodgkin lymphoma and aggressive non-Hodgkin lymphoma clinical trials, get in contact with our Haem B team This email address is being protected from spambots. You need JavaScript enabled to view it..
Open and Recruiting Clinical Trials
INCA036873-101
A Phase 1, Open-Label, Multicenter Study Of INCA036873 In Participants With Advanced Solid Tumors And Hematological Malignancies
Trial IDNCT07195916Cancer typeHematological malignanciesStatusOpen and recruitingPhasePhase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patientsWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
PLATYPS
A Phase I, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of PMCC-COE19 in Patients with CD19-Expressing B-Cell Malignancies
Trial IDACTRN12625001195448Cancer typeB-cell malignanciesStatusOpen to recruitmentPhasePhase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patientsWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
SOUNDTRACK-D2 / D7402C00001
A Phase III, Multicentre, Open-label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP × 2 followed by AZD0486 versus R-mini-CHOP × 6 in Elderly or Unfit Participants with Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2)
Trial IDNCT07215585Cancer typeAcute lymphoblastic leukemia / lymphoblastic lymphomaStatusOpen to recruitmentPhasePhase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.Who can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
Lumi-NHL / D9890C00001
A modular Phase I/II, open-label, multi-center study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of AZD4512 monotherapy or in combination with anti-cancer agent(s) in participants with relapsed/refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)
Trial IDNCT07123454Cancer typeB-cell Non-Hodgkin LymphomaStatusOpen to recruitmentPhasePhase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer Who can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
BGB-16673-104 / PROTAC+
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Trial IDNCT06634589Cancer typeB-cell lymphomasStatusOpen and recruitingPhasePhase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancerWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Trials Registry.
INT2104-101 / INVISE
A Two-Part Open Label Phase 1 Multicentre Study Evaluating the Safety of INT2104 Infusions in Female and Male Participants Aged 18 Years of Age and Older with Refractory/Relapsing B-cell Malignancies
Trial IDNCT06539338Cancer typeB-cell lymphomasStatusOpen and recruitingPhasePhase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer typesWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Trials Registry.
D9960C00001 / TITANium
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies
Trial IDNCT06542250Cancer typeB-cell lymphomasStatusOpen and recruitingPhasePhase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancerWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Trials Registry.
22/012 / EpLCART
A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation With Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
Trial IDNCT06414148Cancer typeLarge B-cell lymphomaStatusOpen and recruitingPhasePhase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer typesWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
KT-US-484-0136 / ZUMA-23
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma
Trial ID
NCT05605899
Cancer type
Large B-cell lymphoma
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
GoldiLox
An Open-label, Single-arm, Phase 2 Trial of GlOfitamab anD pIrtobrutinib (LOXo-305) in Patients With Mantle Cell Lymphoma and Prior Exposure to a BTK Inhibitor
Trial ID
NCT05833763
Cancer type
Mantle cell lymphoma
Status
Open to recruitment
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to ClinicalTrials.gov.
If you don’t find what you are looking for or would like a center closer to home that may also provide similar clinical trials, refer to the Victorian Cancer Trials Link or Australian Clinical Trials Registry.
